

## MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

### BROLUCIZUMAB FOR TREATING WET AGE-RELATED MACULAR DEGENERATION, NICE TA672, FEBRUARY 2021

**RED – RECOMMENDED FOR RESTRICTED USE in Secondary Care**

Name: generic (trade)	What it is	Licensed indications	Decision status	NICE guidance
BROLUCIZUMAB intravitreal injection (Beovu®▼)	Antineovascularisation agent; anti-VEGF humanised monoclonal antibody	Treatment of neovascular (wet) age-related macular degeneration.	Final	NICE TA672 – recommended

#### MSEMOC recommendation:

**Brolucizumab is recommended as an option for treating wet age-related macular degeneration in adults, in accordance with NICE technology appraisal recommendations.**

#### [NICE TA672](#) recommendation:

1.1 Brolucizumab is recommended as an option for treating wet age-related macular degeneration in adults, only if, in the eye to be treated:

- the best-corrected visual acuity is between 6/12 and 6/96
- there is no permanent structural damage to the central fovea
- the lesion size is less than or equal to 12 disc areas in greatest linear dimension and
- there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes).

It is recommended only if the company provides brolucizumab according to the commercial arrangement.

1.2 If patients and their clinicians consider brolucizumab to be one of a range of suitable treatments, including aflibercept and ranibizumab, choose the least expensive (taking into account administration costs and commercial arrangements).

1.3 Only continue brolucizumab in people who maintain an adequate response to therapy. Criteria for stopping should include persistent deterioration in visual acuity and identification of anatomical changes in the retina that indicate inadequate response to therapy.

1.4 These recommendations are not intended to affect treatment with brolucizumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them.

For further information refer to the [Summary of Product Characteristics for brolucizumab](#).

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

<b>References</b>	NICE TA672: Brolucizumab for treating wet age-related macular degeneration: <a href="https://www.nice.org.uk/guidance/ta672">https://www.nice.org.uk/guidance/ta672</a>
<b>Acknowledgements</b>	Mid and South Essex CCGs Medicines Management Teams
<b>Version</b>	1.0
<b>Author</b>	HCPMSEMOC working group
<b>Approved by</b>	MSEMOC; MSE Joint Committee
<b>Date Approved</b>	May 2021
<b>Review Date</b>	May 2026 or sooner if subject to any new updates nationally